ReviewPharmaceuticals (Basel, Switzerland)2021
Behavioral and Psychological Symptoms in Dementia (BPSD) and the Use of Antipsychotics.
Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Barriers and facilitators to accessing and engaging with arts-based non-pharmacological interventions for people living with dementia: A systematic review.Dementia (London, England) · 2026Pooled it
- Predictors and Moderators of Hospitalisation and Mortality in People with Dementia Using Antipsychotics: Systematic Review.Drugs & aging · 2025Pooled it
- Efficacy, acceptability and tolerability of second-generation antipsychotics for behavioural and psychological symptoms of dementia: a systematic review and network meta-analysis.BMJ mental health · 2024Pooled it
- Traditional Chinese medicine Jia Wei Gui Pi Tang improves behavioural and psychological symptoms of dementia and favourable positive emotions in patients.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2023Trial
- A retrospective cohort study on the association between antipsychotics prior to and in the emergency department and their longer-term impacts in older adults with acute agitation.Internal medicine journal · 2026Article
- Prediction of Antipsychotic Drug Doses for BPSD in Alzheimer's Disease Using Deep Learning Techniques.Diagnostics (Basel, Switzerland) · 2026Article
- Development and Exploratory Validation of the Assisting Mealtime Scale for Dementia Care: Nursing Staff Perspectives on Mealtime Support.Nursing & health sciences · 2026Article
- Exploring conditions for implementing daily monitoring of Behavioral and Psychological Symptoms of Dementia (BPSD) in dementia care: insights from a participatory design study.BMC geriatrics · 2026Article
- Brexpiprazole for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease: Clinical Perspectives.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Review
- Palliative Care for People With Very Severe to Extreme Behavioural and Psychological Symptoms of Dementia (BPSD): A Scoping Review.Journal of advanced nursing · 2026Article
- Emotionally Personalized Doll Therapy for Behavioral Symptoms in an 88-Year-Old Woman With Alzheimer's Disease: A Case Report.Clinical case reports · 2026Article
- Use of sensing technologies to assess sleep quality and physical activity levels in nursing home residents with dementia taking nightly psychotropic drugs for sleep disturbance: a cross-sectional study.Frontiers in aging · 2026Article
- Mechanisms of action and advances in application of music therapy in improving cognitive impairment based on the theory of neuroplasticity.Frontiers in neuroscience · 2026Review
- Trends in psychotropic use among older adults with dementia in Korean long-term care hospitals across the COVID-19 pandemic: a national longitudinal study.Frontiers in public health · 2026Article
- The Behaviours in Dementia Toolkit: A Descriptive Study on the Reach and Early Impact of a Digital Health Resource Library About Dementia-Related Mood and Behaviour Changes.Geriatrics (Basel, Switzerland) · 2025Article
- Dementia in a resource-constrained sub-Saharan African setting: A comprehensive retrospective analysis of prevalence, risk factors, and management at the only neuropsychiatric facility in Northeastern Nigeria.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- A matched case-control study on polypharmacy and co-medications one year before drug treatment for Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2025Article
- Evaluating the Therapeutic Efficacy of rTMS Combined with Low-Dose Antipsychotic Medication in Somatic Symptom Disorder.Neuropsychiatric disease and treatment · 2025Article
- Qifuyin alleviates anxiety and depression in 3×Tg-AD mice by modulating neuroendocrine function.Frontiers in psychiatry · 2025Article
- Anticholinergic burden and behavioral and psychological symptoms in older patients with cognitive impairment.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dementia affects about 47 million people worldwide, number expected to exponentially increase within 30 years. Alzheimer's disease (AD) is the most common dementia type, accounting on its own for almost 70% of all dementia cases. Behavioral and psychological symptoms (BPSD) frequently occur during the disease progression; to treat agitation, aggressiveness, delusions and hallucinations, the use of antipsychotic drugs should be limited, due to their safety issues. In this literature review regarding the use of antipsychotics for treating BPSD in dementia, the advantages and limitation of antipsychotic drugs have been evaluated. The available medications for the management of behavioral and psychological symptoms are the antipsychotics, classed into typical and atypical, depending on their action on dopamine and serotonin receptors. First generation, or typical, antipsychotics exhibit lack of tolerability and display a broad range of side effects such as sedation, anticholinergic effects and extrapyramidal symptoms. Atypical, or second generation, antipsychotics bind more selectively to dopamine receptors and simultaneously block serotonin receptors, resulting in higher tolerability. High attention should be paid to the management of therapy interruption or switch between antipsychotics, to limit the possible rebound effect. Several switching strategies may be adopted, and clinicians should "tailor" therapies, accounting for patients' symptoms, comorbidities, polytherapies and frailty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.